Influence of Socio-Economic Factor on Net Survival in Patients With Multiple Sclerosis in France ( ECOVIMUS).

Sponsor
University Hospital, Caen (Other)
Overall Status
Unknown status
CT.gov ID
NCT04028232
Collaborator
Ecole des Hautes Etudes en Santé Publique (Other), Hospices Civils de Lyon (Other)
30,000
18
17.7
1666.7
93.9

Study Details

Study Description

Brief Summary

Background: In comparison to general population, persons with Multiple Sclerosis have a higher risk to premature death with an estimate reduced life expectancy from 7 to 14 years. However, risk factors of mortality in MS are not well identified and well known. Following the example of studies carry on cancers survival, socioeconomic status (SES) may have an influence on survival in MS.

Objective: The main objective of ECOVIMUS is to estimate net survival according to SES using the European Deprivation Index as a proxy and other major covariates (gender, initial clinical phase and years of disease onset).

Methods: In order to answer to our main objective, we will use a retrospective cohort of MS patients with a medical follow-up in one of the 18 centers included in SURVIMUS II, with a MS onset between 1960 and 2015 and with an informed vital at the date of December 31st, 2015.

The ecological score of deprivation EDI will be used as a proxy of the socioeconomic status and will be attributed from the geolocalisation to patient's residence address. Net survival is directly associated to the notion of "mortality in excess". This mortality will be estimated comparing the observed mortality in MS patients to mortality in the general population. The advantage of this methodological approach is that cause of death is not needed.

Statistical analysis: The influence of socioeconomic status on the excess of mortality will be estimated thanks to a parametric multivariate model of excess rate mortality. This model will be adjusted on other major covariates (gender, age at disease onset, and initial clinical phase) and will include potential complex effects as non-linearity, non-proportionality and interactions.

Expected results: We expect to highlight some differences of net survival in MS patients according to socioeconomic group as it was already shown in cancers. This study will complete information on factors of mortality excess in MS and knowledge on socioeconomic inequalities encountered all along MS disease course.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    30000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Other
    Official Title:
    Influence of Socio-Economic Factor on Net Survival in Patients With Multiple Sclerosis in France ( ECOVIMUS).
    Actual Study Start Date :
    Jul 10, 2019
    Anticipated Primary Completion Date :
    Apr 30, 2020
    Anticipated Study Completion Date :
    Dec 31, 2020

    Outcome Measures

    Primary Outcome Measures

    1. Excess mortality survival [From date of MS onset to the date of patients death or to study cut-off date on 1st January 2016.]

      Net survival is defined as the probability of death in a hypothetical setting where the cause of interest (in our case MS) would be the only possible cause of death. It is directly linked to the concept of the "excess mortality due to the studied disease". Net survival can be calculated according to two settings, either the estimator of survival can be calculated from death due to MS while cause of death are known, either it can be calculated from the excess of mortality due to MS compared to the mortality of the general population obtained from mortality table of the generable population.

    Secondary Outcome Measures

    1. European Deprivation Index (EDI) proxy of Socio-Economic Status [From date of MS onset to the date of patients death or to study cut-off date on 1st January 2016.]

      The EDI Score is a combination of weighted ecological variates and is available for each 'IRIS area' (Ilots regroupés pour l'Information Statistique). An IRIS area represents the smallest geographical entity for which census data are available in France. The geolocation of each individual address, according to latitude and longitude coordinates, is performed with the system of geographical information (SGI) ARGIS® 10.5. This point of geolocation is correlated to the IRIS area and then an EDI score can be attributed to patients registered in the database. The EDI score can be categorized into quintiles.

    2. Distance to MS expert care center [From date of MS onset to the date of patients death or to study cut-off date on 1st January 2016.]

      Distance in kilometer by road transport from residence place to MS expert care center

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Year to 100 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    • all patients registered in 17 selected French OFSEP centres with core dataset with a sufficient level of data

    • Diagnosis a of definite or probably MS according to Poser or McDonald criteria. With an MS onset date between January 1st, 1960 and December 31st, 2015.

    • With a postal residence address well informed in the OFSEP database.

    Exclusion Criteria:
    • MS patients with less than one year's disease duration by the study end will be excluded.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Center of CAEN Caen Normandy France 14033
    2 University Hospital of Besancon Besançon France
    3 University Hospital of Bordeaux Bordeaux France
    4 University Hospital Centre of Caen Caen France
    5 University Hospital of Clermont Ferrand Clermont-Ferrand France
    6 University Hospital of Dijon Dijon France
    7 University Hospital of Lille Lille France
    8 University Hospital of Lyon Lyon France
    9 University Hospital of Marseille Marseille France
    10 University Hospital of Montpellier Montpellier France
    11 University Hospital of Nancy Nancy France
    12 University Hospital of Nantes Nantes France
    13 University Hospital of Nice Nice France
    14 University hospital Centre of Nîmes Nîmes France
    15 University Hospital of Rennes Rennes France
    16 University Hospital Centre of Saint-Etienne Saint-Étienne France
    17 University Hospital of Strasbourg Strasbourg France
    18 University Hospital Centre of Toulouse Toulouse France

    Sponsors and Collaborators

    • University Hospital, Caen
    • Ecole des Hautes Etudes en Santé Publique
    • Hospices Civils de Lyon

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Caen
    ClinicalTrials.gov Identifier:
    NCT04028232
    Other Study ID Numbers:
    • 18512
    First Posted:
    Jul 22, 2019
    Last Update Posted:
    Jan 23, 2020
    Last Verified:
    Jan 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Caen
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 23, 2020